APA
Lerman C., Schnoll R. A., Hawk L. W., Cinciripini P., George T. P., Wileyto E. P., Swan G. E., Benowitz N. L., Heitjan D. F. & Tyndale R. F. (20160204). Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. : The Lancet. Respiratory medicine.
Chicago
Lerman Caryn, Schnoll Robert A, Hawk Larry W, Cinciripini Paul, George Tony P, Wileyto E Paul, Swan Gary E, Benowitz Neal L, Heitjan Daniel F and Tyndale Rachel F. 20160204. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. : The Lancet. Respiratory medicine.
Harvard
Lerman C., Schnoll R. A., Hawk L. W., Cinciripini P., George T. P., Wileyto E. P., Swan G. E., Benowitz N. L., Heitjan D. F. and Tyndale R. F. (20160204). Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. : The Lancet. Respiratory medicine.
MLA
Lerman Caryn, Schnoll Robert A, Hawk Larry W, Cinciripini Paul, George Tony P, Wileyto E Paul, Swan Gary E, Benowitz Neal L, Heitjan Daniel F and Tyndale Rachel F. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. : The Lancet. Respiratory medicine. 20160204.